Free Trial

DexCom (DXCM) Financials

DexCom logo
$78.19 +1.79 (+2.34%)
As of 09:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for DexCom

Annual Income Statements for DexCom

This table shows DexCom's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
-22 -58 -66 -50 -127 101 550 217 341 542 576
Consolidated Net Income / (Loss)
-22 -58 -66 -50 -127 101 550 217 341 542 576
Net Income / (Loss) Continuing Operations
-22 -58 -66 -50 -127 101 550 217 341 542 576
Total Pre-Tax Income
-22 -58 -65 -49 -127 104 298 257 391 710 709
Total Operating Income
-22 -57 -64 -43 -186 142 300 266 391 598 600
Total Gross Profit
176 278 378 492 664 932 1,280 1,681 1,883 2,289 2,438
Total Revenue
259 402 573 719 1,032 1,476 1,927 2,449 2,910 3,622 4,033
Operating Revenue
259 402 573 719 1,032 1,476 1,927 2,449 2,910 3,622 4,033
Total Cost of Revenue
83 124 195 226 368 545 647 768 1,027 1,333 1,595
Operating Cost of Revenue
83 124 195 226 368 545 647 768 1,027 1,333 1,595
Total Operating Expenses
198 336 442 535 850 789 981 1,415 1,492 1,691 1,838
Selling, General & Admin Expense
128 198 286 349 433 516 618 811 1,008 1,185 1,286
Research & Development Expense
69 138 156 185 417 274 360 604 484 506 552
Total Other Income / (Expense), net
-0.80 -0.40 -1.00 -6.10 60 -38 -1.60 -9.00 -0.40 113 109
Other Income / (Expense), net
0.00 - - 6.70 2.40 26 16 -9.00 -0.40 113 109
Income Tax Expense
0.10 0.10 0.70 1.60 0.60 3.10 -252 40 50 169 133
Basic Earnings per Share
($0.30) ($0.72) ($0.78) ($0.58) ($1.44) $1.11 $1.46 $0.56 $0.88 $1.40 $1.46
Weighted Average Basic Shares Outstanding
75.20M 79.80M 83.60M 86.30M 88.20M 91.10M 377.50M 386.90M 389.40M 386M 393.60M
Diluted Earnings per Share
($0.30) ($0.72) ($0.78) ($0.58) ($1.44) $1.10 $1.33 $0.53 $0.82 $1.30 $1.42
Weighted Average Diluted Shares Outstanding
75.20M 79.80M 83.60M 86.30M 88.20M 92.30M 420.40M 428.80M 427.50M 425.50M 412.70M
Weighted Average Basic & Diluted Shares Outstanding
75.20M 79.80M 83.60M 86.30M 88.20M 91.59M 96.18M 97.07M 386.41M 385.52M 390.77M

Quarterly Income Statements for DexCom

This table shows DexCom's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders
92 49 116 121 256 146 144 135 152 105 180
Consolidated Net Income / (Loss)
92 49 116 121 256 146 144 135 152 105 180
Net Income / (Loss) Continuing Operations
92 49 116 121 256 146 144 135 152 105 180
Total Pre-Tax Income
133 65 159 240 246 133 188 177 211 154 241
Total Operating Income
125 47 128 206 217 101 158 152 189 134 213
Total Gross Profit
541 463 546 623 657 562 627 594 656 589 689
Total Revenue
815 742 871 975 1,035 921 1,004 994 1,114 1,036 1,157
Operating Revenue
815 742 871 975 1,035 921 1,004 994 1,114 1,036 1,157
Total Cost of Revenue
274 279 325 352 378 359 378 400 458 447 468
Operating Cost of Revenue
274 279 325 352 378 359 378 400 458 447 468
Total Operating Expenses
416 415 418 418 440 461 469 442 467 455 476
Selling, General & Admin Expense
305 296 299 286 304 319 333 306 327 310 328
Research & Development Expense
116 119 119 131 136 142 136 135 140 145 148
Total Other Income / (Expense), net
7.80 17 31 35 29 31 30 25 22 21 29
Other Income / (Expense), net
-1.30 17 31 35 29 31 30 25 22 21 29
Income Tax Expense
41 16 43 120 -10 -14 44 43 60 49 61
Basic Earnings per Share
$0.24 $0.13 $0.30 $0.31 $0.66 $0.38 $0.36 $0.34 $0.38 $0.27 $0.46
Weighted Average Basic Shares Outstanding
389.40M 386.70M 386.70M 386.60M 386M 390.20M 399.20M 394.20M 393.60M 391.10M 392.10M
Diluted Earnings per Share
$0.24 $0.12 $0.28 $0.29 $0.66 $0.36 $0.35 $0.34 $0.37 $0.27 $0.45
Weighted Average Diluted Shares Outstanding
427.50M 418.50M 431.50M 426.80M 425.50M 416.70M 416.80M 410.20M 412.70M 407.50M 408.20M
Weighted Average Basic & Diluted Shares Outstanding
386.41M 387.64M 387.87M 386.37M 385.52M 397.68M 400.73M 390.60M 390.77M 392.11M 392.16M

Annual Cash Flow Statements for DexCom

This table details how cash moves in and out of DexCom's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
29 14 8.40 347 694 -691 372 235 -410 -76 40
Net Cash From Operating Activities
24 49 56 92 123 315 476 443 670 749 990
Net Cash From Continuing Operating Activities
24 49 56 92 123 310 476 443 670 749 990
Net Income / (Loss) Continuing Operations
-22 -58 -66 -50 -127 101 550 217 341 542 576
Consolidated Net Income / (Loss)
-22 -58 -66 -50 -127 101 550 217 341 542 576
Depreciation Expense
8.40 11 15 16 29 49 67 102 156 186 218
Non-Cash Adjustments To Reconcile Net Income
50 121 113 114 264 154 140 240 167 73 131
Changes in Operating Assets and Liabilities, net
-13 -25 -6.30 2.60 -43 6.30 -281 -116 5.10 -52 65
Net Cash From Investing Activities
-17 -52 -56 -144 -140 -1,015 -1,018 -216 -522 -507 -208
Net Cash From Continuing Investing Activities
-17 -52 -56 -144 -140 -1,015 -1,018 -216 -522 -507 -208
Purchase of Property, Plant & Equipment
-16 -33 -56 -66 -67 -180 -199 -389 -365 -237 -359
Acquisitions
0.00 -0.50 0.30 0.00 -11 0.00 0.00 -30 -3.90 0.00 0.00
Purchase of Investments
-14 -45 -39 -172 -453 -2,030 -3,058 -2,473 -2,281 -3,220 -2,658
Sale and/or Maturity of Investments
13 28 39 93 392 1,196 2,251 2,666 2,128 2,947 2,824
Other Investing Activities, net
- - - - -1.00 -1.20 -11 10 0.20 1.90 -16
Net Cash From Financing Activities
22 17 8.10 399 710 11 912 10 -553 -319 -735
Net Cash From Continuing Financing Activities
22 17 8.10 399 710 11 912 10 -553 -319 -735
Repayment of Debt
-2.20 -2.30 -2.30 -75 -1.90 -1.20 -9.40 -9.90 -17 -786 -13
Repurchase of Common Equity
- - 0.00 0.00 -100 - 0.00 0.00 -558 -689 -750
Issuance of Debt
- 0.00 0.00 464 837 0.00 1,189 0.00 0.00 1,231 0.00
Issuance of Common Equity
24 19 10 10 195 12 15 20 23 27 28
Other Financing Activities, net
- - 0.00 0.00 -219 - - 0.00 0.00 -101 0.00
Effect of Exchange Rate Changes
- 0.00 0.00 - - -0.70 2.10 -1.40 -5.80 1.50 -7.40
Cash Interest Paid
0.40 0.30 0.10 2.40 3.60 10 11 12 12 12 11
Cash Income Taxes Paid
0.00 0.10 0.10 1.40 2.30 4.80 3.60 17 114 212 198

Quarterly Cash Flow Statements for DexCom

This table details how cash moves in and out of DexCom's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents
-56 -19 572 -551 -77 285 88 -318 -15 299 254
Net Cash From Operating Activities
133 155 190 269 134 209 279 200 301 184 303
Net Cash From Continuing Operating Activities
132 155 190 269 134 209 279 200 301 184 303
Net Income / (Loss) Continuing Operations
92 49 116 121 256 146 144 135 152 105 180
Consolidated Net Income / (Loss)
92 49 116 121 256 146 144 135 152 105 180
Depreciation Expense
36 42 44 48 53 53 52 55 58 60 63
Non-Cash Adjustments To Reconcile Net Income
38 14 35 22 1.40 33 31 5.40 61 24 47
Changes in Operating Assets and Liabilities, net
-34 52 -4.70 78 -177 -23 53 4.20 31 -5.40 14
Net Cash From Investing Activities
-194 -187 -556 -180 415 75 -189 210 -304 100 -64
Net Cash From Continuing Investing Activities
-194 -187 -556 -180 415 75 -189 210 -304 100 -64
Purchase of Property, Plant & Equipment
-64 -75 -59 -50 -53 -57 -66 -111 -125 -87 -94
Purchase of Investments
-883 -810 -1,340 -798 -272 -992 -784 -307 -574 -463 -608
Sale and/or Maturity of Investments
740 698 859 671 719 1,122 667 631 405 650 639
Net Cash From Financing Activities
-1.00 11 940 -637 -632 4.70 -1.40 -737 -1.60 13 -1.70
Net Cash From Continuing Financing Activities
-1.00 11 940 -637 -632 4.70 -1.40 -737 -1.60 13 -1.70
Repayment of Debt
-1.00 -1.10 -1.10 -652 -132 -8.70 -1.40 -1.30 -1.60 -1.70 -1.70
Effect of Exchange Rate Changes
6.80 1.10 -2.20 -3.50 6.10 -3.80 -1.00 8.60 -11 2.30 17

Annual Balance Sheets for DexCom

This table presents DexCom's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets
185 292 403 904 1,916 2,395 4,291 4,933 5,392 6,265 6,485
Total Current Assets
146 231 280 745 1,700 1,969 3,425 3,684 3,669 4,426 4,301
Cash & Equivalents
72 86 95 442 1,137 446 818 1,053 642 566 606
Short-Term Investments
12 29 29 107 249 1,087 1,890 1,679 1,814 2,158 1,973
Accounts Receivable
42 74 102 134 227 286 429 514 713 974 1,006
Inventories, net
16 35 45 45 71 120 235 357 307 560 543
Prepaid Expenses
3.90 6.80 9.20 17 17 30 54 82 193 168 174
Plant, Property, & Equipment, net
31 55 109 146 183 321 515 802 1,056 1,113 0.00
Total Noncurrent Assets
7.50 6.00 13 14 33 104 350 447 667 726 2,183
Goodwill
3.20 3.70 11 12 19 19 19 27 26 25 23
Intangible Assets
2.70 2.20 - - - - - 32 173 135 103
Noncurrent Deferred & Refundable Income Taxes
- - - - - 0.00 216 291 341 419 481
Other Noncurrent Operating Assets
0.60 0.10 2.10 1.70 15 86 115 99 127 146 1,576
Total Liabilities & Shareholders' Equity
185 292 403 904 1,916 2,395 4,291 4,933 5,392 6,265 6,485
Total Liabilities
44 71 119 485 1,253 1,512 2,464 2,891 3,260 4,196 4,382
Total Current Liabilities
41 67 102 139 222 360 614 721 1,839 1,556 2,932
Short-Term Debt
2.30 2.30 - - - - - 0.00 773 0.00 1,204
Accounts Payable
20 39 68 87 147 256 481 573 902 1,346 1,585
Current Deferred Revenue
0.70 0.80 0.90 3.20 2.90 1.70 2.20 2.10 10 18 8.00
Current Employee Benefit Liabilities
17 25 33 49 72 89 114 125 134 171 112
Other Current Liabilities
- - - - 0.00 14 17 21 21 21 23
Total Noncurrent Liabilities
3.80 3.90 17 346 1,030 1,152 1,850 2,170 1,421 2,640 1,450
Long-Term Debt
2.30 - 0.00 328 1,010 1,060 1,667 1,982 1,198 2,434 1,237
Other Noncurrent Operating Liabilities
1.50 3.90 17 18 20 93 183 189 223 206 213
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
140 221 284 419 663 883 1,827 2,042 2,132 2,069 2,103
Total Preferred & Common Equity
140 221 284 419 663 883 1,827 2,042 2,132 2,069 2,103
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
140 221 284 419 663 883 1,827 2,042 2,132 2,069 2,103
Common Stock
638 777 906 1,094 1,561 1,676 2,125 2,109 2,259 3,515 2,094
Retained Earnings
-498 -555 -621 -672 -799 -696 -202 139 480 1,021 1,598
Treasury Stock
- - - 0.00 -100 -100 -100 -206 -595 -2,451 -1,581
Accumulated Other Comprehensive Income / (Loss)
-0.10 -0.30 -1.00 -2.60 1.50 2.30 3.20 0.50 -12 -17 -8.00

Quarterly Balance Sheets for DexCom

This table presents DexCom's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Total Assets
5,392 5,516 6,821 6,596 6,265 6,482 6,799 6,354 6,485 6,752 7,327
Total Current Assets
3,669 3,767 5,003 4,698 4,426 4,621 4,848 4,263 4,301 4,554 5,030
Cash & Equivalents
642 623 1,195 644 566 851 939 621 606 905 1,159
Short-Term Investments
1,814 1,944 2,441 2,597 2,158 2,046 2,182 1,871 1,973 1,797 1,770
Accounts Receivable
713 637 751 786 974 979 945 1,002 1,006 1,155 1,349
Inventories, net
307 366 421 499 560 589 570 586 543 538 571
Prepaid Expenses
193 198 195 174 168 156 212 182 174 159 181
Plant, Property, & Equipment, net
1,056 1,076 1,078 1,079 1,113 1,109 1,183 1,319 1,340 1,365 0.00
Total Noncurrent Assets
667 673 740 819 726 753 768 772 843 833 2,297
Goodwill
26 26 26 25 25 23 23 24 23 23 24
Intangible Assets
173 164 154 145 135 123 115 106 103 95 87
Noncurrent Deferred & Refundable Income Taxes
341 349 417 501 419 461 476 487 481 487 496
Other Noncurrent Operating Assets
127 135 143 148 146 146 154 156 236 228 1,689
Total Liabilities & Shareholders' Equity
5,392 5,516 6,821 6,596 6,265 6,482 6,799 6,354 6,485 6,752 7,327
Total Liabilities
3,260 3,283 4,720 4,328 4,196 4,235 4,365 4,375 4,382 4,485 4,754
Total Current Liabilities
1,839 1,865 2,070 1,679 1,556 1,594 1,722 1,735 2,932 3,037 3,309
Short-Term Debt
773 773 774 124 0.00 - - - 1,204 1,205 1,206
Accounts Payable
902 965 1,157 1,373 1,346 1,447 1,570 1,593 1,585 1,691 1,944
Current Deferred Revenue
10 9.60 9.00 9.00 18 16 15 14 8.00 7.80 6.10
Current Employee Benefit Liabilities
134 95 109 151 171 111 116 106 112 111 129
Other Current Liabilities
21 22 22 21 21 21 22 22 23 23 23
Total Noncurrent Liabilities
1,421 1,418 2,651 2,650 2,640 2,641 2,643 2,640 1,450 1,448 1,445
Long-Term Debt
1,198 1,199 2,431 2,432 2,434 2,436 2,438 2,440 1,237 1,238 1,239
Other Noncurrent Operating Liabilities
223 219 220 217 206 205 205 201 213 210 206
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
2,132 2,233 2,100 2,268 2,069 2,247 2,434 1,979 2,103 2,267 2,573
Total Preferred & Common Equity
2,132 2,233 2,100 2,268 2,069 2,247 2,434 1,979 2,103 2,267 2,573
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
2,132 2,233 2,100 2,268 2,069 2,247 2,434 1,979 2,103 2,267 2,573
Common Stock
2,259 2,306 2,269 3,618 3,515 2,511 1,993 2,051 2,094 2,143 2,188
Retained Earnings
480 529 644 765 1,021 1,168 1,311 1,446 1,598 1,703 1,883
Accumulated Other Comprehensive Income / (Loss)
-12 -6.50 -29 -36 -17 -37 -38 63 -8.00 2.20 84
Other Equity Adjustments
- - - - - -1,395 - - - - -1,581

Annual Metrics And Ratios for DexCom

This table displays calculated financial ratios and metrics derived from DexCom's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
62.00% 55.09% 42.61% 25.33% 43.58% 43.08% 30.54% 27.08% 18.84% 24.49% 11.34%
EBITDA Growth
38.21% -251.91% -5.86% 78.89% -1,402.91% 240.44% 76.04% -6.25% 52.37% 63.97% 3.38%
EBIT Growth
25.61% -165.58% -11.91% 43.98% -413.69% 191.73% 87.08% -18.63% 52.18% 81.78% -0.20%
NOPAT Growth
25.61% -165.58% -11.91% 33.49% -338.35% 205.87% 300.28% -59.38% 52.14% 33.39% 7.03%
Net Income Growth
24.83% -157.14% -13.89% 23.48% -153.19% 179.54% 443.72% -60.54% 57.31% 58.70% 6.41%
EPS Growth
28.57% -140.00% -8.33% 25.64% -148.28% 176.39% 443.72% -60.54% 54.72% 58.54% 9.23%
Operating Cash Flow Growth
883.33% 107.63% 14.69% 63.70% 33.91% 155.28% 51.22% -6.96% 51.30% 11.80% 32.20%
Free Cash Flow Firm Growth
-88.18% -120.45% -9.61% 29.50% -223.31% 107.76% 929.22% -260.66% 95.87% 2,870.59% -6.53%
Invested Capital Growth
70.54% 79.90% 47.83% 23.92% 45.16% 42.01% 92.18% 64.47% 27.32% 8.07% 10.45%
Revenue Q/Q Growth
14.39% 13.08% 7.58% 7.45% 12.79% 9.24% 5.83% 5.58% 4.19% 6.44% 2.00%
EBITDA Q/Q Growth
22.94% 1.91% -16.47% 73.86% -616.00% 369.06% 0.63% -22.12% 33.11% 18.24% -3.10%
EBIT Q/Q Growth
15.35% 0.00% -13.70% 40.92% -1,795.88% 236.27% -1.16% -30.67% 50.89% 20.75% -4.69%
NOPAT Q/Q Growth
15.35% 0.00% -13.70% 29.87% -1,736.15% 259.32% 91.63% -61.16% 38.66% 42.62% -15.16%
Net Income Q/Q Growth
14.83% 0.35% -15.70% -4.15% -394.21% 159.02% 137.86% -65.76% 39.78% 43.63% -15.36%
EPS Q/Q Growth
18.92% 0.00% -18.18% -1.75% -400.00% 158.51% 137.86% -65.76% 30.16% 32.65% -17.92%
Operating Cash Flow Q/Q Growth
20.41% 6.29% 3.69% 43.53% -5.74% 53.79% 6.33% -13.01% 4.15% 0.15% 20.42%
Free Cash Flow Firm Q/Q Growth
-37.85% -12.09% -6.15% 24.49% -284.62% 107.24% 36.60% -1,163.91% 65.10% 106.07% 29.70%
Invested Capital Q/Q Growth
35.89% 30.64% 19.03% 8.89% 23.98% 7.21% 45.21% 13.23% 15.79% 12.28% 1.99%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
68.02% 69.25% 66.00% 68.49% 64.36% 63.11% 66.44% 68.63% 64.72% 63.19% 60.46%
EBITDA Margin
-5.05% -11.47% -8.51% -1.43% -15.01% 14.73% 19.86% 14.65% 18.79% 24.75% 22.98%
Operating Margin
-8.29% -14.20% -11.15% -5.92% -18.06% 9.64% 15.54% 10.86% 13.44% 16.50% 14.88%
EBIT Margin
-8.29% -14.20% -11.15% -4.98% -17.83% 11.43% 16.38% 10.49% 13.43% 19.61% 17.58%
Profit (Net Income) Margin
-8.64% -14.33% -11.44% -6.99% -12.32% 6.85% 28.53% 8.86% 11.73% 14.95% 14.29%
Tax Burden Percent
100.45% 100.17% 101.08% 103.29% 100.47% 97.03% 184.53% 84.46% 87.31% 76.22% 81.27%
Interest Burden Percent
103.72% 100.70% 101.56% 135.75% 68.79% 61.77% 94.39% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 2.98% -84.53% 15.54% 12.69% 23.78% 18.73%
Return on Invested Capital (ROIC)
-31.52% -47.44% -33.33% -16.60% -53.62% 39.62% 92.49% 21.60% 23.25% 26.61% 26.05%
ROIC Less NNEP Spread (ROIC-NNEP)
-20.11% -29.16% -15.69% -4.73% -54.73% 48.33% 92.88% 22.45% 23.30% 4.46% -15.35%
Return on Net Nonoperating Assets (RNNOA)
11.55% 15.57% 7.35% 2.32% 30.14% -26.54% -51.91% -10.39% -6.90% -0.82% 1.57%
Return on Equity (ROE)
-19.97% -31.88% -25.98% -14.28% -23.48% 13.08% 40.58% 11.21% 16.35% 25.78% 27.63%
Cash Return on Invested Capital (CROIC)
-83.66% -104.53% -71.93% -37.96% -90.46% 4.90% 29.40% -27.15% -0.79% 18.85% 16.12%
Operating Return on Assets (OROA)
-14.00% -23.96% -18.39% -5.48% -13.04% 7.83% 9.44% 5.57% 7.57% 12.19% 11.12%
Return on Assets (ROA)
-14.59% -24.17% -18.88% -7.68% -9.01% 4.69% 16.44% 4.70% 6.61% 9.29% 9.04%
Return on Common Equity (ROCE)
-19.97% -31.88% -25.98% -14.28% -23.48% 13.08% 40.58% 11.21% 16.35% 25.78% 27.63%
Return on Equity Simple (ROE_SIMPLE)
-15.98% -26.04% -23.11% -11.97% -19.16% 11.45% 30.10% 10.62% 16.01% 26.18% 27.40%
Net Operating Profit after Tax (NOPAT)
-15 -40 -45 -30 -130 138 553 225 342 456 488
NOPAT Margin
-5.81% -9.94% -7.80% -4.14% -12.64% 9.35% 28.68% 9.17% 11.74% 12.58% 12.09%
Net Nonoperating Expense Percent (NNEP)
-11.41% -18.28% -17.64% -11.87% 1.11% -8.71% -0.39% -0.85% -0.06% 22.15% 41.40%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 8.33% 10.12% 10.73%
Cost of Revenue to Revenue
31.98% 30.75% 34.00% 31.51% 35.64% 36.89% 33.56% 31.37% 35.28% 36.81% 39.54%
SG&A Expenses to Revenue
49.54% 49.25% 49.92% 48.60% 41.95% 34.94% 32.09% 33.10% 34.63% 32.73% 31.88%
R&D to Revenue
26.77% 34.20% 27.23% 25.80% 40.46% 18.53% 18.68% 24.68% 16.64% 13.96% 13.70%
Operating Expenses to Revenue
76.31% 83.46% 77.15% 74.41% 82.42% 53.47% 50.90% 57.78% 51.27% 46.69% 45.58%
Earnings before Interest and Taxes (EBIT)
-22 -57 -64 -36 -184 169 316 257 391 710 709
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -46 -49 -10 -155 217 383 359 547 896 927
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
7.52 7.52 4.45 2.97 4.01 5.67 4.86 6.37 20.52 23.18 14.45
Price to Tangible Book Value (P/TBV)
7.85 7.73 4.63 3.06 4.13 5.79 4.91 6.56 22.63 25.12 15.37
Price to Revenue (P/Rev)
4.07 4.14 2.20 1.74 2.58 3.39 4.61 5.31 15.03 13.24 7.53
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 49.51 16.15 59.98 128.19 88.54 52.72
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 2.02% 6.19% 1.67% 0.78% 1.13% 1.90%
Enterprise Value to Invested Capital (EV/IC)
16.19 14.33 7.11 5.17 7.94 11.08 9.97 9.48 26.28 26.79 15.39
Enterprise Value to Revenue (EV/Rev)
3.76 3.86 1.98 1.43 2.22 3.07 4.07 5.01 14.86 13.16 7.50
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 20.84 20.47 34.17 79.12 53.16 32.63
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 26.86 24.83 47.75 110.68 67.08 42.65
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 32.82 14.18 54.62 126.64 104.60 62.01
Enterprise Value to Operating Cash Flow (EV/OCF)
41.30 31.67 20.25 11.15 18.55 14.41 16.47 27.71 64.61 63.67 30.56
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 265.53 44.61 0.00 0.00 147.63 100.22
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.03 0.01 0.00 0.78 1.52 1.20 0.91 0.97 0.92 1.18 1.16
Long-Term Debt to Equity
0.02 0.00 0.00 0.78 1.52 1.20 0.91 0.97 0.56 1.18 0.59
Financial Leverage
-0.57 -0.53 -0.47 -0.49 -0.55 -0.55 -0.56 -0.46 -0.30 -0.18 -0.10
Leverage Ratio
1.37 1.32 1.38 1.86 2.60 2.79 2.47 2.38 2.47 2.78 3.06
Compound Leverage Factor
1.42 1.33 1.40 2.52 1.79 1.72 2.33 2.38 2.47 2.78 3.06
Debt to Total Capital
3.18% 1.03% 0.00% 43.86% 60.37% 54.56% 47.72% 49.25% 48.03% 54.06% 53.73%
Short-Term Debt to Total Capital
1.59% 1.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.83% 0.00% 26.51%
Long-Term Debt to Total Capital
1.59% 0.00% 0.00% 43.86% 60.37% 54.56% 47.72% 49.25% 29.20% 54.06% 27.22%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
96.82% 98.97% 100.00% 56.14% 39.63% 45.44% 52.28% 50.75% 51.97% 45.94% 46.27%
Debt to EBITDA
-0.35 -0.05 0.00 -31.81 -6.53 4.87 4.36 5.52 3.60 2.72 2.63
Net Debt to EBITDA
6.03 2.45 0.00 21.46 2.42 -2.18 -2.72 -2.09 -0.89 -0.32 -0.15
Long-Term Debt to EBITDA
-0.18 0.00 0.00 -31.81 -6.53 4.87 4.36 5.52 2.19 2.72 1.33
Debt to NOPAT
-0.31 -0.06 0.00 -11.01 -7.75 7.68 3.02 8.83 5.77 5.34 5.01
Net Debt to NOPAT
5.25 2.82 0.00 7.43 2.88 -3.43 -1.88 -3.34 -1.42 -0.64 -0.28
Long-Term Debt to NOPAT
-0.15 0.00 0.00 -11.01 -7.75 7.68 3.02 8.83 3.51 5.34 2.54
Altman Z-Score
12.17 12.85 5.63 1.97 1.84 3.23 3.57 4.13 9.36 8.59 5.74
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.59 3.46 2.73 5.36 7.64 5.47 5.58 5.11 1.99 2.84 1.47
Quick Ratio
3.10 2.83 2.20 4.92 7.25 5.05 5.11 4.50 1.72 2.38 1.22
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-40 -88 -97 -68 -220 17 176 -282 -12 323 302
Operating Cash Flow to CapEx
145.68% 147.15% 100.90% 139.39% 183.61% 174.72% 239.00% 113.69% 183.53% 316.36% 275.78%
Free Cash Flow to Firm to Interest Expense
-49.94 -220.18 -96.53 -5.32 -9.69 0.28 9.92 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
29.50 122.50 56.20 7.19 5.43 5.22 26.87 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
9.25 39.25 0.50 2.03 2.47 2.23 15.63 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.69 1.69 1.65 1.10 0.73 0.68 0.58 0.53 0.56 0.62 0.63
Accounts Receivable Turnover
7.57 6.90 6.52 6.09 5.72 5.75 5.39 5.19 4.74 4.29 4.07
Inventory Turnover
6.63 4.83 4.84 5.00 6.35 5.72 3.65 2.59 3.09 3.08 2.89
Fixed Asset Turnover
9.99 9.36 6.99 5.64 6.28 5.85 4.61 3.72 3.13 3.34 3.29
Accounts Payable Turnover
4.81 4.17 3.64 2.92 3.14 2.70 1.75 1.46 1.39 1.19 1.09
Days Sales Outstanding (DSO)
48.23 52.89 55.96 59.94 63.86 63.43 67.71 70.27 76.99 85.01 89.58
Days Inventory Outstanding (DIO)
55.04 75.60 75.47 73.03 57.52 63.85 100.06 140.68 118.03 118.57 126.13
Days Payable Outstanding (DPO)
75.95 87.56 100.19 125.19 116.29 135.24 208.16 250.49 262.15 307.58 335.36
Cash Conversion Cycle (CCC)
27.32 40.93 31.24 7.79 5.10 -7.96 -40.39 -39.54 -67.13 -104.01 -119.65
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
60 108 160 198 288 409 786 1,293 1,646 1,779 1,965
Invested Capital Turnover
5.43 4.77 4.27 4.01 4.24 4.24 3.22 2.36 1.98 2.12 2.15
Increase / (Decrease) in Invested Capital
25 48 52 38 90 121 377 507 353 133 186
Enterprise Value (EV)
975 1,552 1,138 1,026 2,286 4,532 7,835 12,261 43,254 47,655 30,239
Market Capitalization
1,054 1,665 1,262 1,247 2,661 5,005 8,876 13,011 43,740 47,945 30,377
Book Value per Share
$1.83 $2.72 $3.36 $4.83 $7.47 $9.64 $19.02 $21.07 $5.52 $5.35 $5.38
Tangible Book Value per Share
$1.75 $2.65 $3.22 $4.69 $7.26 $9.44 $18.82 $20.47 $5.00 $4.94 $5.06
Total Capital
145 224 284 747 1,674 1,942 3,494 4,024 4,102 4,503 4,544
Total Debt
4.60 2.30 0.00 328 1,010 1,060 1,667 1,982 1,970 2,434 2,441
Total Long-Term Debt
2.30 0.00 0.00 328 1,010 1,060 1,667 1,982 1,198 2,434 1,237
Net Debt
-79 -113 -124 -221 -375 -474 -1,041 -749 -486 -290 -138
Capital Expenditures (CapEx)
16 33 56 66 67 180 199 389 365 237 359
Debt-free, Cash-free Net Working Capital (DFCFNWC)
24 52 54 57 92 76 103 232 146 146 -5.60
Debt-free Net Working Capital (DFNWC)
108 167 178 606 1,477 1,609 2,811 2,964 2,602 2,870 2,574
Net Working Capital (NWC)
105 164 178 606 1,477 1,609 2,811 2,964 1,830 2,870 1,369
Net Nonoperating Expense (NNE)
7.35 18 21 20 -3.31 37 2.95 7.60 0.35 -86 -89
Net Nonoperating Obligations (NNO)
-80 -113 -124 -221 -375 -474 -1,041 -749 -486 -290 -138
Total Depreciation and Amortization (D&A)
8.40 11 15 26 29 49 67 102 156 186 218
Debt-free, Cash-free Net Working Capital to Revenue
9.26% 12.81% 9.40% 7.96% 8.87% 5.14% 5.35% 9.49% 5.01% 4.03% -0.14%
Debt-free Net Working Capital to Revenue
41.51% 41.47% 30.98% 84.31% 143.19% 109.02% 145.88% 121.04% 89.43% 79.23% 63.82%
Net Working Capital to Revenue
40.63% 40.90% 30.98% 84.31% 143.19% 109.02% 145.88% 121.04% 62.87% 79.23% 33.95%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.30) ($0.72) ($0.78) ($0.58) ($1.44) $1.11 $5.23 $1.60 $0.88 $1.40 $1.46
Adjusted Weighted Average Basic Shares Outstanding
77.51M 81.74M 84.82M 87.00M 90.00M 91.10M 94.40M 96.70M 389.40M 386M 393.60M
Adjusted Diluted Earnings per Share
($0.30) ($0.72) ($0.78) ($0.58) ($1.44) $1.10 $5.06 $1.55 $0.82 $1.30 $1.42
Adjusted Weighted Average Diluted Shares Outstanding
77.51M 81.74M 84.82M 87.00M 90.00M 92.30M 97.50M 100.10M 427.50M 425.50M 412.70M
Adjusted Basic & Diluted Earnings per Share
($0.30) ($0.72) ($0.78) ($0.58) ($1.44) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
75.20M 79.80M 83.60M 86.30M 88.20M 91.59M 96.18M 97.07M 386.41M 385.52M 390.77M
Normalized Net Operating Profit after Tax (NOPAT)
-15 -40 -45 -30 -130 138 210 225 342 456 488
Normalized NOPAT Margin
-5.81% -9.94% -7.80% -4.14% -12.64% 9.35% 10.88% 9.17% 11.74% 12.58% 12.09%
Pre Tax Income Margin
-8.60% -14.30% -11.32% -6.76% -12.26% 7.06% 15.46% 10.49% 13.43% 19.61% 17.58%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-26.88 -142.75 -63.90 -2.80 -8.10 2.80 17.83 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-18.81 -99.93 -44.73 -2.32 -5.74 2.29 31.22 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-47.13 -226.00 -119.60 -7.95 -11.06 -0.19 6.59 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-39.06 -183.18 -100.43 -7.48 -8.70 -0.70 19.98 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% -78.68% 0.00% 0.00% 0.00% 163.45% 127.18% 130.16%

Quarterly Metrics And Ratios for DexCom

This table displays calculated financial ratios and metrics derived from DexCom's official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
16.76% 17.92% 25.15% 26.69% 26.90% 24.21% 15.26% 1.97% 7.64% 12.49% 15.21%
EBITDA Growth
557.38% 37.26% 64.24% 55.66% 86.22% 74.36% 18.18% -19.37% -9.91% 15.84% 26.76%
EBIT Growth
1,711.69% 59.26% 99.13% 64.43% 98.39% 105.43% 17.89% -26.21% -14.18% 16.45% 28.38%
NOPAT Growth
17,493.57% -68.05% 79.06% 1.06% 161.27% 214.09% 29.54% 11.78% -39.94% -18.24% 31.32%
Net Income Growth
1,832.08% -50.05% 127.70% 19.27% 179.19% 201.23% 23.81% 11.52% -40.81% -28.01% 25.30%
EPS Growth
2,500.00% -47.83% 133.33% 20.83% 175.00% 200.00% 25.00% 17.24% -43.94% -25.00% 28.57%
Operating Cash Flow Growth
25.24% 118.87% 10.13% -8.19% 0.83% 34.62% 46.82% -25.89% 125.60% -12.14% 8.45%
Free Cash Flow Firm Growth
47.40% 65.90% 63.48% 66.43% 134.86% 73.07% 135.45% -280.35% -154.07% -260.97% -571.54%
Invested Capital Growth
27.32% 11.64% 13.63% 11.45% 8.07% 9.04% 4.96% 21.59% 10.45% 12.47% 19.26%
Revenue Q/Q Growth
5.93% -9.04% 17.51% 11.90% 6.10% -10.97% 9.04% -1.01% 12.00% -6.96% 11.69%
EBITDA Q/Q Growth
-13.48% -33.85% 91.33% 42.17% 3.50% -38.27% 29.68% -3.00% 15.64% -20.36% 41.90%
EBIT Q/Q Growth
-15.12% -48.03% 146.98% 50.91% 2.41% -46.40% 41.74% -5.54% 19.11% -26.98% 56.25%
NOPAT Q/Q Growth
-15.35% -58.85% 162.06% 10.71% 118.84% -50.53% 8.08% -4.47% 17.59% -32.66% 73.60%
Net Income Q/Q Growth
-9.29% -47.06% 138.48% 4.14% 112.34% -42.88% -1.98% -6.20% 12.70% -30.52% 70.59%
EPS Q/Q Growth
0.00% -50.00% 133.33% 3.57% 127.59% -45.45% -2.78% -2.86% 8.82% -27.03% 66.67%
Operating Cash Flow Q/Q Growth
-54.81% 17.28% 22.46% 41.46% -50.37% 56.59% 33.56% -28.60% 51.08% -39.02% 64.85%
Free Cash Flow Firm Q/Q Growth
-50.21% 49.35% 20.82% 44.28% 255.98% -139.13% 204.22% -697.88% 77.83% -161.27% -36.14%
Invested Capital Q/Q Growth
15.79% -0.50% 1.89% -5.06% 12.28% 0.40% -1.93% 9.99% 1.99% 2.23% 4.00%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
66.40% 62.39% 62.71% 63.93% 63.47% 61.01% 62.40% 59.73% 58.90% 56.85% 59.53%
EBITDA Margin
19.68% 14.31% 23.30% 29.60% 28.87% 20.09% 23.89% 23.41% 24.17% 20.69% 26.28%
Operating Margin
15.38% 6.37% 14.70% 21.08% 20.97% 10.98% 15.73% 15.29% 16.96% 12.91% 18.37%
EBIT Margin
15.22% 8.70% 18.28% 24.66% 23.80% 14.39% 18.70% 17.84% 18.98% 14.89% 20.84%
Profit (Net Income) Margin
11.26% 6.55% 13.30% 12.38% 24.78% 15.90% 14.29% 13.54% 13.62% 10.17% 15.54%
Tax Burden Percent
68.92% 75.35% 72.76% 50.21% 104.10% 110.49% 76.41% 75.87% 71.79% 68.31% 74.57%
Interest Burden Percent
107.33% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
31.08% 24.65% 27.24% 49.79% -4.10% -10.49% 23.59% 24.13% 28.21% 31.69% 25.43%
Return on Invested Capital (ROIC)
21.00% 9.34% 21.81% 23.96% 46.17% 26.94% 27.66% 26.13% 26.24% 19.27% 30.69%
ROIC Less NNEP Spread (ROIC-NNEP)
20.13% 7.36% 18.08% 20.74% 38.31% 20.37% 23.58% 20.90% 18.73% 15.36% 27.05%
Return on Net Nonoperating Assets (RNNOA)
-5.96% -2.19% -5.06% -5.51% -7.08% -4.80% -5.80% -3.62% -1.92% -2.45% -6.31%
Return on Equity (ROE)
15.04% 7.15% 16.75% 18.46% 39.10% 22.14% 21.87% 22.51% 24.32% 16.83% 24.39%
Cash Return on Invested Capital (CROIC)
-0.79% 6.85% 7.54% 10.42% 18.85% 22.61% 28.10% 13.25% 16.12% 12.68% 8.51%
Operating Return on Assets (OROA)
8.58% 4.97% 9.71% 14.60% 14.79% 9.12% 10.80% 10.90% 12.01% 9.34% 12.69%
Return on Assets (ROA)
6.35% 3.75% 7.07% 7.33% 15.40% 10.07% 8.26% 8.27% 8.62% 6.38% 9.46%
Return on Common Equity (ROCE)
15.04% 7.15% 16.75% 18.46% 39.10% 22.14% 21.87% 22.51% 24.32% 16.83% 24.39%
Return on Equity Simple (ROE_SIMPLE)
0.00% 13.10% 17.02% 16.62% 0.00% 28.45% 27.40% 34.40% 0.00% 23.61% 0.00%
Net Operating Profit after Tax (NOPAT)
86 36 93 103 226 112 121 115 136 91 159
NOPAT Margin
10.60% 4.80% 10.70% 10.58% 21.83% 12.13% 12.02% 11.60% 12.18% 8.82% 13.70%
Net Nonoperating Expense Percent (NNEP)
0.87% 1.98% 3.72% 3.22% 7.86% 6.57% 4.09% 5.23% 7.52% 3.91% 3.64%
Return On Investment Capital (ROIC_SIMPLE)
2.11% - - - 5.01% - - - 2.98% 1.94% 3.16%
Cost of Revenue to Revenue
33.60% 37.61% 37.29% 36.07% 36.53% 38.99% 37.60% 40.27% 41.10% 43.15% 40.47%
SG&A Expenses to Revenue
37.45% 39.97% 34.32% 29.37% 29.35% 34.67% 33.13% 30.82% 29.40% 29.93% 28.35%
R&D to Revenue
14.27% 16.05% 13.69% 13.48% 13.16% 15.36% 13.54% 13.62% 12.53% 14.02% 12.81%
Operating Expenses to Revenue
51.02% 56.02% 48.01% 42.85% 42.50% 50.03% 46.67% 44.44% 41.93% 43.95% 41.15%
Earnings before Interest and Taxes (EBIT)
124 65 159 240 246 133 188 177 211 154 241
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
160 106 203 289 299 185 240 233 269 214 304
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
20.52 20.10 23.72 15.96 23.18 23.85 18.52 13.57 14.45 11.77 13.30
Price to Tangible Book Value (P/TBV)
22.63 21.97 25.94 17.25 25.12 25.52 19.63 14.53 15.37 12.42 13.90
Price to Revenue (P/Rev)
15.03 14.85 15.58 10.63 13.24 14.10 11.46 6.79 7.53 6.43 7.96
Price to Earnings (P/E)
128.19 153.48 139.34 95.99 88.54 83.83 67.61 39.46 52.72 49.86 59.89
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.78% 0.65% 0.72% 1.04% 1.13% 1.19% 1.48% 2.53% 1.90% 2.01% 1.67%
Enterprise Value to Invested Capital (EV/IC)
26.28 27.05 29.60 22.41 26.79 29.75 25.35 13.92 15.39 13.16 16.15
Enterprise Value to Revenue (EV/Rev)
14.86 14.66 15.44 10.43 13.16 13.97 11.29 6.78 7.50 6.37 7.85
Enterprise Value to EBITDA (EV/EBITDA)
79.12 76.97 75.41 46.83 53.16 54.47 43.87 28.04 32.63 27.64 33.07
Enterprise Value to EBIT (EV/EBIT)
110.68 106.79 99.95 60.35 67.08 68.25 55.03 36.04 42.65 36.16 43.03
Enterprise Value to NOPAT (EV/NOPAT)
126.64 159.88 155.09 111.14 104.60 99.28 78.84 46.65 62.01 57.04 67.37
Enterprise Value to Operating Cash Flow (EV/OCF)
64.61 58.76 64.02 47.50 63.67 66.22 49.82 32.63 30.56 27.41 34.16
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 416.42 417.71 226.66 147.63 137.26 92.43 115.26 100.22 109.85 206.41
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.92 0.88 1.53 1.13 1.18 1.08 1.00 1.23 1.16 1.08 0.95
Long-Term Debt to Equity
0.56 0.54 1.16 1.07 1.18 1.08 1.00 1.23 0.59 0.55 0.48
Financial Leverage
-0.30 -0.30 -0.28 -0.27 -0.18 -0.24 -0.25 -0.17 -0.10 -0.16 -0.23
Leverage Ratio
2.47 2.39 2.76 2.81 2.78 2.68 3.00 3.05 3.06 2.93 2.82
Compound Leverage Factor
2.66 2.39 2.76 2.81 2.78 2.68 3.00 3.05 3.06 2.93 2.82
Debt to Total Capital
48.03% 46.89% 60.41% 52.99% 54.06% 52.02% 50.04% 55.21% 53.73% 51.88% 48.72%
Short-Term Debt to Total Capital
18.83% 18.39% 14.59% 2.57% 0.00% 0.00% 0.00% 0.00% 26.51% 25.59% 24.04%
Long-Term Debt to Total Capital
29.20% 28.50% 45.82% 50.42% 54.06% 52.02% 50.04% 55.21% 27.22% 26.29% 24.69%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
51.97% 53.11% 39.59% 47.01% 45.94% 47.98% 49.96% 44.79% 46.27% 48.12% 51.28%
Debt to EBITDA
3.60 3.43 4.89 3.37 2.72 2.50 2.41 2.55 2.63 2.56 2.40
Net Debt to EBITDA
-0.89 -1.03 -0.66 -0.90 -0.32 -0.47 -0.67 -0.06 -0.15 -0.27 -0.47
Long-Term Debt to EBITDA
2.19 2.08 3.71 3.21 2.72 2.50 2.41 2.55 1.33 1.30 1.21
Debt to NOPAT
5.77 7.12 10.06 8.00 5.34 4.55 4.33 4.24 5.01 5.27 4.88
Net Debt to NOPAT
-1.42 -2.15 -1.36 -2.14 -0.64 -0.86 -1.21 -0.09 -0.28 -0.56 -0.97
Long-Term Debt to NOPAT
3.51 4.33 7.63 7.61 5.34 4.55 4.33 4.24 2.54 2.67 2.47
Altman Z-Score
9.20 9.34 7.53 6.36 8.34 9.06 7.69 5.20 5.49 4.88 5.66
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.99 2.02 2.42 2.80 2.84 2.90 2.82 2.46 1.47 1.50 1.52
Quick Ratio
1.72 1.72 2.12 2.40 2.38 2.43 2.36 2.01 1.22 1.27 1.29
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-267 -135 -107 -60 93 -36 38 -227 -50 -131 -179
Operating Cash Flow to CapEx
208.66% 208.03% 322.54% 534.13% 254.48% 367.66% 422.69% 179.41% 241.89% 211.26% 322.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.56 0.57 0.53 0.59 0.62 0.63 0.58 0.61 0.63 0.63 0.61
Accounts Receivable Turnover
4.74 5.12 4.88 5.04 4.29 4.71 4.64 4.42 4.07 3.89 3.75
Inventory Turnover
3.09 3.04 3.03 3.04 3.08 2.96 2.96 2.79 2.89 2.99 3.11
Fixed Asset Turnover
3.13 3.13 3.17 3.27 3.34 3.48 3.48 3.30 3.29 3.35 0.00
Accounts Payable Turnover
1.39 1.37 1.25 1.15 1.19 1.17 1.08 1.02 1.09 1.07 1.01
Days Sales Outstanding (DSO)
76.99 71.33 74.85 72.39 85.01 77.55 78.65 82.51 89.58 93.88 97.34
Days Inventory Outstanding (DIO)
118.03 120.24 120.38 120.18 118.57 123.31 123.39 130.69 126.13 122.26 117.42
Days Payable Outstanding (DPO)
262.15 266.27 291.97 317.27 307.58 311.37 339.32 357.24 335.36 340.25 361.58
Cash Conversion Cycle (CCC)
-67.13 -74.70 -96.75 -124.70 -104.01 -110.52 -137.28 -144.04 -119.65 -124.11 -146.82
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,646 1,638 1,669 1,584 1,779 1,786 1,751 1,926 1,965 2,009 2,089
Invested Capital Turnover
1.98 1.95 2.04 2.26 2.12 2.22 2.30 2.25 2.15 2.19 2.24
Increase / (Decrease) in Invested Capital
353 171 200 163 133 148 83 342 186 223 337
Enterprise Value (EV)
43,254 44,298 49,383 35,505 47,655 53,129 44,406 26,812 30,239 26,428 33,743
Market Capitalization
43,740 44,894 49,815 36,188 47,945 53,590 45,089 26,865 30,377 26,686 34,227
Book Value per Share
$5.52 $5.78 $5.42 $5.85 $5.35 $5.76 $6.12 $4.94 $5.38 $5.80 $6.56
Tangible Book Value per Share
$5.00 $5.29 $4.95 $5.41 $4.94 $5.38 $5.77 $4.61 $5.06 $5.50 $6.28
Total Capital
4,102 4,205 5,305 4,825 4,503 4,683 4,872 4,419 4,544 4,710 5,018
Total Debt
1,970 1,972 3,204 2,557 2,434 2,436 2,438 2,440 2,441 2,443 2,445
Total Long-Term Debt
1,198 1,199 2,431 2,432 2,434 2,436 2,438 2,440 1,237 1,238 1,239
Net Debt
-486 -595 -432 -684 -290 -461 -683 -53 -138 -258 -484
Capital Expenditures (CapEx)
64 75 59 50 53 57 66 111 125 87 94
Debt-free, Cash-free Net Working Capital (DFCFNWC)
146 109 71 -96 146 130 5.50 36 -5.60 21 -1.70
Debt-free Net Working Capital (DFNWC)
2,602 2,676 3,707 3,144 2,870 3,027 3,126 2,528 2,574 2,722 2,928
Net Working Capital (NWC)
1,830 1,902 2,933 3,020 2,870 3,027 3,126 2,528 1,369 1,517 1,722
Net Nonoperating Expense (NNE)
-5.38 -13 -23 -18 -31 -35 -23 -19 -16 -14 -21
Net Nonoperating Obligations (NNO)
-486 -595 -432 -684 -290 -461 -683 -53 -138 -258 -484
Total Depreciation and Amortization (D&A)
36 42 44 48 53 53 52 55 58 60 63
Debt-free, Cash-free Net Working Capital to Revenue
5.01% 3.59% 2.21% -2.83% 4.03% 3.41% 0.14% 0.91% -0.14% 0.50% -0.04%
Debt-free Net Working Capital to Revenue
89.43% 88.52% 115.93% 92.39% 79.23% 79.61% 79.45% 63.94% 63.82% 65.62% 68.07%
Net Working Capital to Revenue
62.87% 62.94% 91.73% 88.74% 79.23% 79.61% 79.45% 63.94% 33.95% 36.56% 40.03%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.24 $0.13 $0.30 $0.31 $0.66 $0.38 $0.36 $0.34 $0.38 $0.27 $0.46
Adjusted Weighted Average Basic Shares Outstanding
389.40M 386.70M 386.70M 386.60M 386M 390.20M 399.20M 394.20M 393.60M 391.10M 392.10M
Adjusted Diluted Earnings per Share
$0.24 $0.12 $0.28 $0.29 $0.66 $0.36 $0.35 $0.34 $0.37 $0.27 $0.45
Adjusted Weighted Average Diluted Shares Outstanding
427.50M 418.50M 431.50M 426.80M 425.50M 416.70M 416.80M 410.20M 412.70M 407.50M 408.20M
Adjusted Basic & Diluted Earnings per Share
$0.24 $0.00 $0.00 $0.00 $0.66 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
386.41M 387.64M 387.87M 386.37M 385.52M 397.68M 400.73M 390.60M 390.77M 392.11M 392.16M
Normalized Net Operating Profit after Tax (NOPAT)
86 36 93 103 152 71 121 115 136 91 159
Normalized NOPAT Margin
10.60% 4.80% 10.70% 10.58% 14.68% 7.68% 12.02% 11.60% 12.18% 8.82% 13.70%
Pre Tax Income Margin
16.34% 8.70% 18.28% 24.66% 23.80% 14.39% 18.70% 17.84% 18.98% 14.89% 20.84%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
163.45% 0.00% 208.78% 50.05% 127.18% 0.00% 74.97% 183.61% 130.16% 0.00% 0.00%

Key Financial Trends

DexCom (NASDAQ:DXCM) has demonstrated strong financial performance and growth trends over the last four years through Q2 2025. Key takeaways from the latest quarterly and annual cash flow, income, and balance sheet statements include:

  • Strong revenue growth: Operating revenue rose consistently from $741.5 million in Q1 2023 to $1.157 billion in Q2 2025, showing robust market demand and successful product expansion.
  • Improved profitability: Net income increased from $48.6 million in Q1 2023 to $179.8 million in Q2 2025. Diluted EPS improved from $0.12 to $0.45 over this period, reflecting effective cost management and scale benefits.
  • Expanding operating margin: Gross profit margin increased from approximately 40.4% in Q1 2023 to about 59.5% in Q2 2025, driven by higher revenue and controlled cost of revenue.
  • Healthy operating cash flow: Quarterly net cash from operating activities jumped from $155 million in Q1 2023 to $303 million in Q2 2025, signaling strong cash-generating ability from core operations.
  • Solid balance sheet with growing equity: Total shareholders' equity rose from around $2.24 billion in Q1 2023 to over $2.57 billion in Q2 2025, accompanied by stable or slightly increased total assets.
  • Stable debt levels: Total liabilities have increased moderately, largely due to consistent long-term debt around $1.2 billion but remain manageable relative to equity and cash flow.
  • Increased capital expenditures: Investments in property, plant, and equipment and acquisitions (amortization and intangible assets) fluctuated but indicate ongoing investment into the business infrastructure and innovation.
  • Currency exchange effects: Some impact on cash flow due to exchange rate changes is noted, positive in recent quarters but with occasional negative effects in prior years.
  • Rising operating expenses: Selling, general & administrative (SGA) and research & development (R&D) expenses have grown alongside revenue, from $415 million to $476 million total operating expenses (Q1 2023 vs Q2 2025), indicating increased investment which needs monitoring for efficiency.
  • Volatility in investing cash flows: Net cash used in investing activities is sometimes very high, e.g., -$555 million (Q2 2023) and -$63.6 million (Q2 2025), reflecting large purchases of investments and property that could impact liquidity if not matched by operational cash flow.

Overall, DexCom shows a positive multi-year trend in revenue, profitability, and cash flow generation, supported by strong operational performance and growing equity base. Incremental investments and expenses correspond with scaling efforts, while maintaining manageable debt levels. Retail investors should watch for continued revenue growth and operational efficiency to sustain these favorable trends.

08/08/25 08:58 AMAI Generated. May Contain Errors.

Frequently Asked Questions About DexCom's Financials

When does DexCom's financial year end?

According to the most recent income statement we have on file, DexCom's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has DexCom's net income changed over the last 10 years?

DexCom's net income appears to be on an upward trend, with a most recent value of $576.20 million in 2024, falling from -$22.40 million in 2014. The previous period was $541.50 million in 2023. See where experts think DexCom is headed by visiting DexCom's forecast page.

What is DexCom's operating income?
DexCom's total operating income in 2024 was $600 million, based on the following breakdown:
  • Total Gross Profit: $2.44 billion
  • Total Operating Expenses: $1.84 billion
How has DexCom's revenue changed over the last 10 years?

Over the last 10 years, DexCom's total revenue changed from $259.20 million in 2014 to $4.03 billion in 2024, a change of 1,455.9%.

How much debt does DexCom have?

DexCom's total liabilities were at $4.38 billion at the end of 2024, a 4.4% increase from 2023, and a 9,769.1% increase since 2014.

How much cash does DexCom have?

In the past 10 years, DexCom's cash and equivalents has ranged from $71.80 million in 2014 to $1.14 billion in 2018, and is currently $606.10 million as of their latest financial filing in 2024.

How has DexCom's book value per share changed over the last 10 years?

Over the last 10 years, DexCom's book value per share changed from 1.83 in 2014 to 5.38 in 2024, a change of 194.0%.



This page (NASDAQ:DXCM) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners